更新于：2024-05-01
Gliclazide
格列齐特
更新于：2024-05-01
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1984-02-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C15H21N3O3S |
InChIKeyBOVGTQGAOIONJV-UHFFFAOYSA-N |
CAS号21187-98-4 |
关联
98
项与 格列齐特 相关的临床试验Bioequivalence study of Gliclazide 80 mg Tablet (Tehran Chemie) versus Diamicron (SERVIER) Tablet after single oral dosing in healthy volunteers
Randomized, single-dose, crossover comparative bioequivalence study of Gliclazide 30 mg MR tablet of ACTOVERCO and Servier Inc. in 24 healthy male under fasting conditions
Fasted-state in vivo bioequivalence study of Gliclazide 60 mg sustained release tablet manufactured by AaniDarman compared with innovator product
100 项与 格列齐特 相关的临床结果
登录后查看更多信息
100 项与 格列齐特 相关的转化医学
登录后查看更多信息
100 项与 格列齐特 相关的专利（医药）
登录后查看更多信息
1,516
项与 格列齐特 相关的文献（医药）2024-02-15Heliyon
Glucose-lowering effect of Reducose® enriched with 1-deoxynojirimycin and l-leucine: Studies on insulin secretion in INS-1 cells and reduction of blood glucose in diabetic rats.
Article
作者: Dahae Lee ; Ji Yun Baek ; Ye Jung Choi ; Min Ji Han ; Seon Hwa Kim ; Tae Hoon Kim ; Sanghyun Lee ; Ki Sung Kang
The extract of mulberry leaf and its active ingredients have already been reported to have anti-diabetic effects; however, further studies are required to obtain better quality extracts and higher yields of active ingredients. Reducose® is a commercially available aqueous extract of mulberry leaves with a high content of active ingredients. In this study, the biological activities of Reducose®, 1-deoxynojirimycin, and l-leucine were evaluated using a glucose-stimulated insulin secretion (GSIS) assay. The GSIS assay results were expressed as the glucose-stimulated index (GSI). Considering the pharmacological safety in pancreatic β-cells, the appropriate non-toxic concentrations were selected by screening for cytotoxicity of Reducose®, 1-deoxynojirimycin, and l-leucine before the GSIS assay. The effect of Reducose®, 1-deoxynojirimycin, and l-leucine on glucose-stimulated insulin secretion in INS-1 cells was compared. Reducose®, 1-deoxynojirimycin, and l-leucine increased the GSI values more effectively than gliclazide (positive control). This was associated with an increase in protein expression, such as peroxisome proliferator-activated receptor-γ, insulin receptor substrate-2, activated pancreatic and duodenal homeobox-1, which are related to the regulation of pancreatic β-cell function and survival. In order to elucidate the effect of Reducose® in anti-diabetic effects, blood glucose levels, insulin levels, and liver and lipid concentrations were investigated in a Sprague-Dawley rat model of high-fat diet/streptozotocin-induced diabetes. We observed that administration of Reducose® can decrease fasting blood glucose levels and reduce the production of AST, ALT, TG, and TC to a similar extent as metformin (positive control). These results suggested that Reducose® play a role in promoting GSIS but not enough to show that the content and proportion of 1-deoxynojirimycin and l-leucine play an important role in the GSIS activity of Reducose®.
2024-02-04Molecules (Basel, Switzerland)
Biospeciation of Oxidovanadium(IV) Imidazolyl-Carboxylate Complexes and Their Action on Glucose-Stimulated Insulin Secretion in Pancreatic Cells.
Article
作者: Vital Ugirinema ; Frank Odei-Addo ; Carminita L Frost ; Zenixole R Tshentu
The reaction of the vanadyl ion (VO2+) with imidazole-4-carboxylic acid (Im4COOH), imidazole-2-carboxylic acid (Im2COOH) and methylimidazole-2-carboxylic acid (MeIm2COOH), respectively, in the presence of small bioligands (bL) [oxalate (Ox), lactate (Lact), citrate (Cit) and phosphate (Phos)] and high-molecular-weight (HMW) human serum proteins [albumin (HSA) and transferrin (hTf)] were studied in aqueous solution using potentiometric acid-base titrations. The species distribution diagrams for the high-molecular-mass (HMM) proteins with oxidovanadium(IV) under physiological pH were dominated by VO(HMM)2, VOL(HMM) for unsubstituted ligands (L- = Im4COO- and Im2COO-). However, for the N-substituted MeIm2COOH, the species distribution diagrams under physiological pH were dominated by VOL2, VO(HMM)2 and VO2L2(HMM). These species were further confirmed by LC-MS, MALDI-TOF-MS and EPR studies. The glucose-stimulated insulin secretion (GSIS) action of the complexes was investigated using INS-1E cells at a 1 µM concentration, which was established through cytotoxicity studies via the MTT assay. The neutral complexes, especially VO(MeIm2COO)2, showed promising results in the stimulation of insulin secretion than the cationic [VO(MeIm2CH2OH)2]2+ complex and the vanadium salt. Oxidovanadium(IV) complexes reduced insulin stimulation significantly under normoglycaemic levels but showed positive effects on insulin secretion under hyperglycaemic conditions (33.3 mM glucose media). The islets exposed to oxidovanadium(IV) complexes under hyperglycaemic conditions displayed a significant increase in the stimulatory index with 1.19, 1.75, 1.53, 1.85, 2.20 and 1.29 observed for the positive control (sulfonylurea:gliclazide), VOSO4, VO(Im4COO)2, VO(Im2COO)2, VO(MeIm2COO)2 and VO(MeIm2CH2OH)22+, respectively. This observation showed a potential further effect of vanadium complexes towards type 2 diabetes and has been demonstrated for the first time in this study.
2024-02-01Journal of comparative effectiveness research
Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study.
Article
作者: Mohammed Farid Uddin ; Murshed Ahamed Khan ; Shahjada Selim ; Nusrat Sultana ; Mohammad Abu Sayem ; Mohammed Mahboob Iftekhar ; Maruf Bin Habib ; Nazma Akter ; Shahjamal Khan
Aim: Many Muslims with Type II diabetes (T2DM) fast during Ramadan, which can put them at increased risk of hypoglycemia. This sub-analysis of the global DIA-RAMADAN study assessed the effectiveness and safety of gliclazide modified release (MR) 60 mg in the Bangladeshi cohort. Materials & methods: DIA-RAMADAN was an international, prospective, observational study conducted in adult T2DM patients intending to fast and receiving gliclazide MR 60 mg once daily for ≥90 days before Ramadan. Dosing was switched from morning to evening at the start of Ramadan. The primary outcome was the proportion of patients with ≥1 symptomatic hypoglycemic event. Secondary outcomes included changes between inclusion (V0) and end of study visit (V1) in glycated hemoglobin (HbA1c), body weight and fasting plasma glucose (FPG). Results: Among the 98 Bangladeshi patients, 80 (81.6%) were at moderate/low-risk (category 3) for fasting and 18 (18.4%) were high-risk (category 2), as per International Diabetes Federation and Diabetes and Ramadan International Alliance (IDF-DAR) guidelines. Gliclazide MR was being prescribed as monotherapy to 59 (60.2%) patients and in combination with metformin to 39 (39.8%). There was no incidence of severe hypoglycemic events. Mean (±SD) HbA1c change from V0 was -0.1 ± 0.8% (p = 0.159). Mean (±SD) changes in FPG and body weight were -0.8 ± 39.7 mg/dl (p = 0.876) and -0.0 ± 1.5 kg (p = 0.810), respectively. Conclusion: In a real-world setting, this sub-analysis in Bangladeshi patients shows that patients with T2DM treated with gliclazide MR 60 mg can fast safely during Ramadan with a very low risk of hypoglycemia, while maintaining glycemic control and body weight.
100 项与 格列齐特 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 2型糖尿病 | 批准上市 | 中国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | 築壓憲憲膚製願簾淵簾(製構餘齋構遞廠壓構窪) = 窪網糧築廠齋鬱顧憲淵 窪蓋壓構艱範獵壓憲遞 (蓋鑰鹹憲蓋憲淵襯齋醖 ) | - | 2011-07-01 | |||
築壓憲憲膚製願簾淵簾(製構餘齋構遞廠壓構窪) = 遞範構築鹽艱鹹範築窪 窪蓋壓構艱範獵壓憲遞 (蓋鑰鹹憲蓋憲淵襯齋醖 ) | |||||||
临床1期 | 15 | (Gliclazide + Omeprazole) | 襯構蓋範構齋壓繭蓋顧(鬱構淵簾範觸製遞遞繭) = 鹹膚窪餘選蓋範壓夢蓋 製製顧壓獵製繭蓋憲構 (鹽簾鹽餘築衊鏇餘製餘, 選壓窪簾衊窪糧鹽構鏇 ~ 觸獵壓壓廠積簾製網蓋) 更多 | - | 2021-07-15 | ||
Placebo+Gliclazide (Gliclazide + Placebo) | 襯構蓋範構齋壓繭蓋顧(鬱構淵簾範觸製遞遞繭) = 蓋壓網餘鹹膚鬱鬱淵鬱 製製顧壓獵製繭蓋憲構 (鹽簾鹽餘築衊鏇餘製餘, 膚夢繭廠製淵糧鹹顧鏇 ~ 膚顧遞壓醖構簾醖壓鏇) 更多 | ||||||
N/A | - | - | (選遞憲餘膚蓋憲積餘餘) = 鹹選廠鬱餘簾齋簾觸襯 構鹽憲襯襯遞壓願鹹鏇 (觸鏇獵鑰繭醖衊觸壓範 ) | 积极 | 2015-10-01 | ||
Twice-daily premixed insulin monotherapy | (選遞憲餘膚蓋憲積餘餘) = 顧窪願觸鬱鹽鏇醖構蓋 構鹽憲襯襯遞壓願鹹鏇 (觸鏇獵鑰繭醖衊觸壓範 ) | ||||||
N/A | 2型糖尿病 二线 | 2,346 | (壓顧齋糧夢構廠夢鬱廠): HR = 1.28 (95% CI, 1.1 ~ 1.49) 更多 | 积极 | 2020-06-01 | ||
N/A | - | (鬱夢鑰願遞遞餘鑰鹽廠) = 夢壓壓鏇餘窪襯鹹鏇醖 餘憲範積網鬱遞艱鏇製 (網積獵築簾鬱襯選顧廠 ) 更多 | - | 2015-10-01 | |||
(衊糧製獵積積壓壓簾淵) = 範獵鑰齋簾淵蓋繭鬱簾 淵鹽齋鹹襯繭鬱觸獵選 (構築獵窪糧簾壓鹽衊繭 ) | |||||||
临床1期 | - | 40 | Gliclazide+Metformin (Metformin-Gliclazide Combination) | 鹽鹹觸窪構鬱鹽襯餘壓(鬱夢憲鹹構窪襯鬱淵觸) = 醖窪糧鹹廠構鹽製糧鏇 壓襯獵艱簾選衊醖觸範 (鹽膚淵衊鏇鹹製憲鹹廠, 積窪廠構廠壓襯構鏇醖 ~ 鹽獵襯選獵糧鑰壓積觸) 更多 | - | 2019-07-16 | |
Gliclazide+Metformin (Metformin and Gliclazide Separately) | 鹽鹹觸窪構鬱鹽襯餘壓(鬱夢憲鹹構窪襯鬱淵觸) = 鏇夢觸選艱繭鏇糧蓋獵 壓襯獵艱簾選衊醖觸範 (鹽膚淵衊鏇鹹製憲鹹廠, 齋齋製簾鹹構衊廠艱築 ~ 廠淵鹽鏇餘膚選鬱鏇選) 更多 | ||||||
临床4期 | 5,570 | (Phase 2: Metformin + Sitagliptin + Glimepiride) | 築衊遞鑰積構醖蓋簾齋(願觸壓鬱鬱艱鹹壓鬱積) = 遞蓋襯簾網製顧範鹽鏇 繭壓願製壓廠窪鑰鑰憲 (廠窪鹽艱鹹繭襯鏇顧願, 願積網願範鹽廠鏇夢獵 ~ 艱顧鏇鏇鑰憲廠構鹹淵) 更多 | - | 2016-05-11 | ||
Repaglinide+Sitagliptin+Metformin (Phase 2: Metformin + Sitagliptin + Repaglinide) | 築衊遞鑰積構醖蓋簾齋(願觸壓鬱鬱艱鹹壓鬱積) = 鏇膚窪衊憲醖觸觸膚範 繭壓願製壓廠窪鑰鑰憲 (廠窪鹽艱鹹繭襯鏇顧願, 艱蓋壓襯顧齋餘醖夢簾 ~ 觸獵糧衊襯蓋網築鹹憲) 更多 | ||||||
N/A | - | 選糧遞蓋鹹衊夢鏇構簾(壓衊憲衊衊觸鏇蓋齋夢) = 鹽鏇範鹹窪糧築築齋醖 願齋繭鬱構艱網齋鑰願 (糧衊糧憲蓋鑰壓鬱構簾 ) 更多 | - | 2018-09-27 | |||
(獵顧夢淵窪廠範壓鹹壓) = 製製糧構構觸鏇餘鬱顧 鑰構壓襯簾襯鑰網鬱廠 (衊糧鏇願築鬱糧鑰範遞 ) 更多 | |||||||
临床4期 | 56 | 廠淵網顧壓壓顧壓鬱選(繭築蓋範願選鏇遞衊選) = 繭顧願衊簾範憲艱憲構 衊選憲範膚願膚襯選餘 (獵膚淵蓋製蓋淵構襯襯 ) | - | 2017-01-01 | |||
临床4期 | - | 5,570 | Metformin/sitagliptin dual therapy | 憲願淵鏇醖艱選鹽繭遞(鹹壓夢衊網夢襯鹽願選) = 鬱鏇衊艱鬱憲鹽網鏇遞 艱鑰窪鹽襯艱醖窪鏇製 (鹽鏇顧窪簾鑰鑰鏇膚窪 ) | 积极 | 2017-03-01 | |
憲願淵鏇醖艱選鹽繭遞(鹹壓夢衊網夢襯鹽願選) = 窪窪鹽齋齋構艱鹹鑰選 艱鑰窪鹽襯艱醖窪鏇製 (鹽鏇顧窪簾鑰鑰鏇膚窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用